Takeda presents rare bleeding disorders research at thrombosis & hemostasis summit of north america (thsna) 2020

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse: 4502/nyse:tak) (“takeda”), today presented four abstracts at the thrombosis and hemostasis summit of north america (thsna), highlighting takeda's commitment to advancing personalized care in people living with bleeding disorders. these studies may help provide further data to healthcare providers regarding treatment personalization in patients with hemophilia and von willebrand's disease (vwd). “when l
TAK Ratings Summary
TAK Quant Ranking